- Home
- TVTX
as 12-18-2024 10:43am EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.6B | IPO Year: | N/A |
| Target Price: | $23.46 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.12 - $20.33 | Next Earning Date: | 02-13-2025 |
| Revenue: | $203,447,000 | Revenue Growth: | 57.08% |
| Revenue Growth (this year): | 62.17% | Revenue Growth (next year): | 56.38% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LYONS GARY A | TVTX | Director | Oct 4 '24 | Sell | $14.75 | 40,000 | $589,100.78 | 69,821 | |
| Meckler Jeffrey A | TVTX | Director | Sep 30 '24 | Sell | $14.06 | 40,000 | $562,324.00 | 81,000 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
Travere Therapeutics to Present at Upcoming Investor Conferences
Simply Wall St.
a month ago
Exploring Three High Growth Tech Stocks in the United States
GlobeNewswire
a month ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire
a month ago
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire
a month ago
Travere Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire
a month ago
Travere Therapeutics to Present at Upcoming Investor Conferences
Simply Wall St.
2 months ago
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.